CytoMed Therapeutics (FRA:F98) Other Current Liabilities: €0.02 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:F98 CytoMed Therapeutics Ltd FRA:F98
19 GF Score
Price €0.76
! 2 Warning Signs
View Full Analysis

What is CytoMed Therapeutics Other Current Liabilities?

CytoMed Therapeutics FRA:F98 -9.58% 19 Other Current Liabilities is €0.02 Mil as of Dec. 2025. GuruFocus rates FRA:F98 with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

CytoMed Therapeutics's other current liabilities for the quarter that ended in Dec. 2025 was €0.02 Mil.

CytoMed Therapeutics's quarterly other current liabilities increased from Dec. 2024 (€0.01 Mil) to Jun. 2025 (€0.06 Mil) but then declined from Jun. 2025 (€0.06 Mil) to Dec. 2025 (€0.02 Mil).

CytoMed Therapeutics's annual other current liabilities declined from Dec. 2023 (€0.10 Mil) to Dec. 2024 (€0.01 Mil) but then increased from Dec. 2024 (€0.01 Mil) to Dec. 2025 (€0.02 Mil).

CytoMed Therapeutics Other Current Liabilities Related Terms

CytoMed Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for CytoMed Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoMed Therapeutics Other Current Liabilities Chart

CytoMed Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.10 0.01 0.02

CytoMed Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.10 0.00 0.01 0.06 0.02
FRA:F98
19GF Score
CytoMed Therapeutics Ltd FRA:F98
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoMed Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €0.02 Mil mean?
CytoMed Therapeutics (FRA:F98) has a Other Current Liabilities of €0.02 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on CytoMed Therapeutics.
Is CytoMed Therapeutics' Other Current Liabilities too high?
CytoMed Therapeutics' current Other Current Liabilities is €0.02 Mil. Overall, CytoMed Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' Other Current Liabilities compare to LEXX and INAB?
CytoMed Therapeutics' Other Current Liabilities of €0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on CytoMed Therapeutics. CytoMed Therapeutics's current Other Current Liabilities is €0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (FRA:F98) has a current Other Current Liabilities of €0.02 Mil. The current Other Current Liabilities is €0.02 Mil. CytoMed Therapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For CytoMed Therapeutics (FRA:F98), the current Other Current Liabilities is €0.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoMed Therapeutics Business Description

Other Exchanges GDTC:USA
Address 1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
19GF Score

Get the complete analysis for FRA:F98

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.76
Price